References:
1. Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy
remains the primary treatment option for severely symptomatic patients
with obstructive hypertrophic cardiomyopathy. Circulation
2007;116(2):196-206; discussion 206.
2. Makhija N, Magoon R, Balakrishnan I, Das S, Malik V, Gharde P. Left
ventricular outflow tract obstruction following aortic valve
replacement: A review of risk factors, mechanism, and management. Ann
Card Anaesth 2019;22(1):1-5.
3. Bartunek J, Sys SU, Rodrigues AC, van Schuerbeeck E, Mortier L, de
Bruyne B. Abnormal systolic intraventricular flow velocities after valve
replacement for aortic stenosis. Mechanisms, predictive factors, and
prognostic significance. Circulation 1996;93(4):712-9.
4. Sigwart U. Non-surgical myocardial reduction for hypertrophic
obstructive cardiomyopathy. Lancet 1995;346(8969):211-4.
5. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F,
Greenberg NL, Agler DA, Drinko JK and others. Outcome of patients with
hypertrophic obstructive cardiomyopathy after percutaneous transluminal
septal myocardial ablation and septal myectomy surgery. J Am Coll
Cardiol 2001;38(7):1994-2000.
6. Kato M, Miyahara M, Suzuki H, Uchida F, Nishimura Y, Nishikawa H. A
case of successful percutaneous transluminal septal myocardial ablation
for heart failure due to severe left ventricular outflow obstruction
with Monckeberg’s arteriosclerosis, manifested after aortic valvular
replacement. Cardiovasc Interv Ther 2015;30(1):72-7.